Recently, Peking University People's Hospital Professor HUANG Xiaojun research team published a paper entitled "Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority randomized phase 3 trial " in Lancet Oncology, the top international journal of clinical oncology.

　　The results of this study prove that "no infusion, no chemotherapy" cures acute promyelocytic leukemia (APL), and provides the highest level of evidence in Evidence-base Medicine for non-high-risk APL treatment in the new era. It makes the treatment of acute promyelocytic leukemia more convenient, avoids many side effects brought by chemotherapy, saves the hospitalization days for over 4 months, thus greatly improving patients’ quality of life and reducing patients’ burden of medical expenses as well.

　　This research makes the research of APL in China steadily rank first in the world and it has become the key force to promote the development in this field.

　　Professor HUANG Xiaojun  Chief Physician

　　Written by: WU Zhaoxia

　　Edited by:Liu Xin

　　Source: Peking University People’s Hospital